Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

SEHK:2252
SEHK:2252Medical Equipment

Shanghai MicroPort MedBot (SEHK:2252) Valuation After Global Toumai Robot Orders And Remote Surgery Progress

Shanghai MicroPort MedBot (Group) (SEHK:2252) is back on investors’ radar after reporting more than 200 commercial orders for its Toumai laparoscopic surgical robot, with around 130 systems installed across nearly 50 countries and regions. See our latest analysis for Shanghai MicroPort MedBot (Group). The recent Toumai order momentum and remote surgery progress come as the shares trade at HK$29.0, with an 11.71% 1 day share price return and 22.99% 90 day share price return, alongside a 50.57%...
ENXTPA:OR
ENXTPA:ORPersonal Products

L'Oréal (ENXTPA:OR) Margin Slip To 13.9% Tests Premium Valuation Narrative

L'Oréal (ENXTPA:OR) has put fresh numbers on the table for FY 2025, with second half revenue of €21.6b, basic EPS of €5.17 and net income of €2.8b, alongside trailing 12 month revenue of €44.1b, EPS of €11.48 and net income of €6.1b. The group has seen revenue move from €21.4b in the second half of 2024 to €21.6b in the latest half, while basic EPS shifted from €5.15 to €5.17 over the same periods. This sets up a story where investors are weighing solid top line scale against a slightly...
NasdaqGM:RPD
NasdaqGM:RPDSoftware

Rapid7 (RPD) Guides to 2026 Profitability After Q4 Results Is Its Margin Story Evolving?

In February 2026, Rapid7, Inc. reported its fourth-quarter 2025 results, with revenue of US$217.39 million and net income of US$3.13 million, alongside full-year 2025 revenue of US$859.79 million and net income of US$23.38 million. The company also issued 2026 guidance that points to a GAAP loss in the first quarter but a return to GAAP profitability for the full year, giving investors fresh insight into its near-term growth and margin path. Now we’ll examine how Rapid7’s modest quarterly...
ENXTAM:HEIO
ENXTAM:HEIOBeverage

Is It Time To Reassess Heineken Holding (ENXTAM:HEIO) After Recent Share Price Strength

For investors considering whether Heineken Holding shares offer good value at around €70.85, this article explores what the current price might be implying about the business. The stock has returned 6.7% over the past week, 14.3% over the last 30 days and 14.2% year to date, while the 1 year return sits at 5.4% and the 3 year return at a 2.3% decline. Recent attention on the stock has been driven by ongoing interest in global consumer staples and how large beverage brands are positioned, as...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Is It Time To Reassess Exact Sciences (EXAS) After The US$105 Abbott Offer?

If you are wondering whether Exact Sciences is still worth your attention at current prices, the key question is how its market value compares with what the business may be worth on paper. The stock last closed at US$103.24, with returns of 0.1% over 7 days, 1.0% over 30 days, 1.5% year to date, 109.4% over 1 year, 62.6% over 3 years, and a 30.2% decline over 5 years. Recent news around Exact Sciences has focused on its position in cancer diagnostics and how its core products fit into...